The estimated Net Worth of Arthur Tzianabos is at least $7.12 millió dollars as of 13 February 2024. Arthur Tzianabos owns over 31,739 units of Homology Medicines Inc stock worth over $29,517 and over the last 7 years he sold FIXX stock worth over $2,031,256. In addition, he makes $5,062,880 as President, Chief Executive Officer és Director at Homology Medicines Inc.
Sign up
Arthur Tzianabos FIXX stock SEC Form 4 insiders trading
Arthur has made over 15 trades of the Homology Medicines Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 31,739 units of FIXX stock worth $69,508 on 13 February 2024.
The largest trade he's ever made was exercising 33,420 units of Homology Medicines Inc stock on 1 January 2024 worth over $31,081. On average, Arthur trades about 8,838 units every 57 days since 2018. As of 13 February 2024 he still owns at least 31,739 units of Homology Medicines Inc stock.
You can see the complete history of Arthur Tzianabos stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Arthur Tzianabos biography
Dr. Arthur O. Tzianabos Ph.D. serves as President, Chief Executive Officer, Director of the Company. Dr. Tzianabos joined Homology from OvaScience, Inc., a biotechnology company (which has since merged with and into Millendo Therapeutics, Inc.), where he served as President and Chief Scientific Officer from September 2013 to March 2016. Prior to OvaScience, Dr. Tzianabos spent eight years at Shire plc, a biotechnology company, where he served in positions of increasing responsibility, including Senior Director, Discovery Research, Vice President, Program Management and Senior Vice President and Head, Research and Early Development. From 1992 to 2005, Dr. Tzianabos was a faculty member at Harvard Medical School and maintained laboratories at the Channing Laboratory, Brigham and Women’s Hospital and the Department of Microbiology and Molecular Genetics at Harvard Medical School. Dr. Tzianabos currently serves as a director of Stoke Therapeutics, Inc. Dr. Tzianabos previously served as a director of BIND Therapeutics, Inc. Dr. Tzianabos holds a B.S. in Biology from Boston College and a Ph.D. in Microbiology from the University of New Hampshire. Tzianabos’ extensive academic and clinical experience, as well as his knowledge of the industry, qualifies him to serve on our Board of Directors.
What is the salary of Arthur Tzianabos?
As the President, Chief Executive Officer és Director of Homology Medicines Inc, the total compensation of Arthur Tzianabos at Homology Medicines Inc is $5,062,880. There are no executives at Homology Medicines Inc getting paid more.
How old is Arthur Tzianabos?
Arthur Tzianabos is 57, he's been the President, Chief Executive Officer és Director of Homology Medicines Inc since 2016. There are 8 older and 9 younger executives at Homology Medicines Inc. The oldest executive at Homology Medicines Inc is Steven Gillis, 67, who is the Independent Director.
What's Arthur Tzianabos's mailing address?
Arthur's mailing address filed with the SEC is C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVENUE, BEDFORD, MA, 01730.
Insiders trading at Homology Medicines Inc
Over the last 7 years, insiders at Homology Medicines Inc have traded over $108,214,465 worth of Homology Medicines Inc stock and bought 3,033,333 units worth $51,999,993 . The most active insiders traders include Steven Gillis, James Edeerfield Management... és Kush Parmar. On average, Homology Medicines Inc executives and independent directors trade stock every 26 days with the average trade being worth of $106,785. The most recent stock trade was executed by Paul Alloway on 25 March 2024, trading 23,530 units of FIXX stock currently worth $21,883.
What does Homology Medicines Inc do?
homology medicines is a genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases.
What does Homology Medicines Inc's logo look like?
Complete history of Arthur Tzianabos stock trades at Homology Medicines Inc, Akouos és Stoke Therapeutics
Homology Medicines Inc executives and stock owners
Homology Medicines Inc executives and other stock owners filed with the SEC include:
-
Arthur Tzianabos,
President, Chief Executive Officer, Director -
Tim Kelly,
Chief Technical Operations Officer -
Albert Seymour,
Chief Scientific Officer -
W. Bradford Smith,
Chief Financial Officer, Treasurer and Secretary -
Dr. Arthur O. Tzianabos Ph.D.,
Pres, CEO & Director -
Dr. Albert Seymour Ph.D.,
Chief Scientific Officer -
W. Bradford Smith CPA, M.B.A.,
CFO & Treasurer -
Alise Reicin,
Independent Director -
Kush Parmar,
Independent Director -
Mary Thistle,
Independent Director -
Richard Gregory,
Independent Director -
Matthew Patterson,
Independent Director -
Steven Gillis,
Independent Director -
Jeffrey Poulton,
Director -
Gabriel Cohn,
Chief Medical Officer -
Cara Mayfield,
Director of Corp. Communications -
Dr. Deborah Kinch Ph.D.,
Chief Devel. Officer -
Dr. Julie Jordan M.D.,
Sr. VP and Head of Clinical Devel. & Operations -
Michael Blum M.B.A.,
Chief Commercial Officer -
Dr. Gabriel M. Cohn M.B.A., M.D.,
Chief Medical Officer -
Melissa Gelormini,
VP of HR -
Theresa McNeely,
Chief Communications Officer & Patient Advocate -
Dr. Paul Alloway J.D., Ph.D.,
Chief Legal Officer & Sec. -
Timothy P. Kelly M.B.A.,
Chief Operating Officer -
Dr. Saswati Chatterjee Ph.D.,
Co-Founder & Member of Scientific Advisory Board -
Ventures Iv, L.P.5 Am Co In...,
-
Ventures Iv, L.P.5 Am Partn...,
-
Institutes For Bio Medical ...,
-
Ventures, Llcvv Manager Llc...,
-
Holdings (Private) Ltd Full...,
-
Cameron Wheeler,
Director -
Siyamak Rasty,
Chief Operating Officer -
James Edeerfield Management...,
-
James Edeerfield Management...,
-
Venture Fund Viii, L.P.Arch...,
-
Springs Capital Management ...,
-
Venture Fund Viii, L.P.Arch...,
-
Charles Jr Michaud,
See Remarks -
Paul Alloway,
See Remarks -
Michael Lee Blum,
Chief Commercial Officer -
Julie Jordan,
Chief Medical Officer